FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2702344249> ?p ?o ?g. }

• W2702344249 endingPage "655" @default.
• W2702344249 startingPage "653" @default.
• W2702344249 abstract "While proteasome inhibitors are now well-established research tools and chemotherapeutics, proteasome activators are much less explored. In this issue of Cell Chemical Biology, in a study from the groups of Berkers and Ovaa (Leestemaker et al., 2017Leestemaker Y. de Jong A. Witting K.F. Penning R. Schuurman K. Rodenko B. Zaal E.A. van de Kooij B. Laufer S. Heck A.J.R. et al.Cell Chem. Biol. 2017; 24 (this issue): 725-736Abstract Full Text Full Text PDF PubMed Scopus (87) Google Scholar), a chemical screen was used to identify a p38 MAPK inhibitor as a proteasome activator. This compound furthermore enhanced clearance of protein aggregates, thereby implicating alternative chemotherapeutic options for treating neurodegenerative diseases. While proteasome inhibitors are now well-established research tools and chemotherapeutics, proteasome activators are much less explored. In this issue of Cell Chemical Biology, in a study from the groups of Berkers and Ovaa (Leestemaker et al., 2017Leestemaker Y. de Jong A. Witting K.F. Penning R. Schuurman K. Rodenko B. Zaal E.A. van de Kooij B. Laufer S. Heck A.J.R. et al.Cell Chem. Biol. 2017; 24 (this issue): 725-736Abstract Full Text Full Text PDF PubMed Scopus (87) Google Scholar), a chemical screen was used to identify a p38 MAPK inhibitor as a proteasome activator. This compound furthermore enhanced clearance of protein aggregates, thereby implicating alternative chemotherapeutic options for treating neurodegenerative diseases. The ubiquitin-proteasome system (UPS) represents the core machinery of regulated protein degradation and is involved in almost all cellular processes. Many small molecule modulators of various components of the UPS are available, and chemical modulation of the UPS has emerged as a promising strategy for developing novel chemotherapies (Huang and Dixit, 2016Huang X. Dixit V.M. Cell Res. 2016; 26: 484-498Crossref PubMed Scopus (305) Google Scholar, Nalepa et al., 2006Nalepa G. Rolfe M. Harper J.W. Nat. Rev. Drug Discov. 2006; 5: 596-613Crossref PubMed Scopus (517) Google Scholar); e.g., through inhibition of the proteasome as the proteolytic “heart” of the UPS. Indeed, by far most known UPS modulators act via inhibition of the UPS. In contrast, the alternative approach, namely, small molecule mediated UPS activation by direct proteasome activation, has so far been much less explored (Lee et al., 2010Lee B.H. Lee M.J. Park S. Oh D.C. Elsasser S. Chen P.C. Gartner C. Dimova N. Hanna J. Gygi S.P. et al.Nature. 2010; 467: 179-184Crossref PubMed Scopus (707) Google Scholar), despite its potential as a new chemotherapeutic approach, especially in the treatment of various neurodegenerative disorders (Chondrogianni et al., 2015Chondrogianni N. Voutetakis K. Kapetanou M. Delitsikou V. Papaevgeniou N. Sakellari M. Lefaki M. Filippopoulou K. Gonos E.S. Ageing Res. Rev. 2015; 23: 37-55Crossref PubMed Scopus (77) Google Scholar). The lack of a suitable screening approach to identify proteasome activators is one reason why such promising compounds are currently not forthcoming. The persistent challenge to elucidate such direct proteasome activators has now been taken up by the groups of Celia R. Berkers and Huib Ovaa (Leestemaker et al., 2017Leestemaker Y. de Jong A. Witting K.F. Penning R. Schuurman K. Rodenko B. Zaal E.A. van de Kooij B. Laufer S. Heck A.J.R. et al.Cell Chem. Biol. 2017; 24 (this issue): 725-736Abstract Full Text Full Text PDF PubMed Scopus (87) Google Scholar). To this end, they first established a novel FACS-based high-throughput screen for directly measuring proteasome activity in living cells. This assay was based on a known proteasome-directed activity-based probe (ABP) that binds to the proteasomal active sites in an activity-dependent manner (Figure 1A) (Verdoes et al., 2006Verdoes M. Florea B.I. Menendez-Benito V. Maynard C.J. Witte M.D. van der Linden W.A. van den Nieuwendijk A.M. Hofmann T. Berkers C.R. van Leeuwen F.W. et al.Chem. Biol. 2006; 13: 1217-1226Abstract Full Text Full Text PDF PubMed Scopus (140) Google Scholar). Cellular proteasome activity is regulated by diverse factors; for example by regulating spatial access to the proteolytic sites via a gating mechanism (Figure 1B) (Finley et al., 2016Finley D. Chen X. Walters K.J. Trends Biochem. Sci. 2016; 41: 77-93Abstract Full Text Full Text PDF PubMed Scopus (178) Google Scholar). The ABP is tagged with a fluorophore so that labeling of active proteasomes results in a fluorescence signal. Its intensity thereby correlates with proteasome activity and can be directly quantified in living cells via FACS. A cellular pre-incubation with chemical modulators before application of the proteasome ABP will thus allow a technically simple cell-based screening for chemical proteasome activators and inhibitors. By screening a library of 2750 compounds, the authors were able to identify overall 11 small molecules with diverse chemical structures that amplified proteasomal activity (Figure 1C). Of these, one compound, PD169316, was particularly interesting because it is a known active site p38 MAPK inhibitor, thereby indicating a regulatory link between the p38 MAPK signaling pathway and the UPS. Accordingly, the authors focused their studies on this compound and the corresponding signal transduction cascade. To confirm that the observed proteasome activation indeed stemmed from p38 MAPK inhibition, the proteasome activation assay was repeated with another set of commercially available p38 MAPK inhibitors, among them the highly p38α-selective compound skepinone-L, as well as via siRNA experiments versus all four p38 MAPK isoforms. Interestingly, in both experiment series, inhibition or downregulation of p38α MAPK resulted in the highest proteasome activation. To better understand which component of the p38 MAPK pathway besides p38α MAPK contributes to proteasome activation, the authors performed an siRNA screen for depleting all major kinases of this signaling pathway. They found the upstream components ASK1 and MKK6 as well as the downstream kinase MK2 as proteasome activity modulating factors. This indicates that proteasome activity is at least partly modulated by the kinase MK2 and application of the pharmacological MK2 inhibitor III indeed led to proteasome activation (Figure 1D). The authors therefore next asked how the p38 MAPK pathway affects proteasome activity. This could for example be achieved by post-translational modification, in particular phosphorylation, of the proteasome. To test whether p38 MAPK inhibition-mediated proteasome activation is persistent, the authors used a tagged proteasome species that allowed isolation of proteasomes after p38 MAPK pathway inhibition. Indeed, they found that isolated proteasomes retained their higher proteolytic activity resulting from p38 MAPK inhibition, indicating that the observed activation is caused by direct proteasome modulation such as post-translational modifications. However, all further experiments to better understand the molecular basis of this effect did not reveal a clear mechanism. For example, phosphoproteomics analyses of the proteasome after MAPK pathway inhibition showed no significant changes in the phosphosite signature. All other tested known proteasome activity influencing factors, such as proteasome assembly or differential recruitment of proteasome-associated factors, were also uninfluenced by p38 MAPK inhibitor treatments. In the last part of their study, the authors then turned their attention to the biomedical applicability of proteasome activation via p38 MAPK pathway inhibition. To this end, they first determined the maximal level of proteasome activation that can be achieved by impairing this pathway. High activation levels up to 4-fold were reached, particularly at low basal proteasome activity levels, as, for example, observed in neurodegenerative disease conditions. This amplification of proteolytic activity, however, did not result in a massive increase in proteasomal protein turnover, but only in changes in levels of selected proteins in accordance with the known finding that under normal cellular conditions, ubiquitination and not degradation represents the rate-limiting step in the proteolysis of most proteins. For proteins with artificially triggered ubiquitination, as, for example, through the use of a PROTAC approach that forces ubiquitination of target proteins (Lai and Crews, 2017Lai A.C. Crews C.M. Nat. Rev. Drug Discov. 2017; 16: 101-114Crossref PubMed Scopus (705) Google Scholar), p38 MAPK inhibition increased protein degradation rates. Finally, the authors were also able to show that p38 MAPK pathway inhibition increased clearance of toxic protein assemblies via a cell-based α-synuclein aggregation model. In such conditions, proteasome activity is usually very low, and these experiments therefore strongly indicate that proteasome activation is not resulting in massive, potentially harmful cellular changes under normal but only under non-homeostatic conditions. Proteasome activation might thus represent a feasible alternative chemotherapeutic strategy to combat neurodegenerative diseases. Altogether, the study by Berkers and Ovaa represents an impressive advance in the development of chemical tools and the biomedical exploitation and our functional understanding of the ubiquitin-proteasome system (Leestemaker et al., 2017Leestemaker Y. de Jong A. Witting K.F. Penning R. Schuurman K. Rodenko B. Zaal E.A. van de Kooij B. Laufer S. Heck A.J.R. et al.Cell Chem. Biol. 2017; 24 (this issue): 725-736Abstract Full Text Full Text PDF PubMed Scopus (87) Google Scholar). First, they were able to develop a systematic high-throughput screening approach for identifying direct small molecule proteasome activators that despite a limited set of only 2750 compounds, delivered many starting points for chemical probe development. Clearly, a repetition of the screening campaign with a larger small molecule library has the potential to identify further, chemically distinct proteasome activators that might then be further developed into tool compounds or even drugs. Such compounds, with in addition a subsequent target identification approach, may thus reveal many novel and scientifically rewarding insights into the cellular regulation of proteasome activity. In fact, the focused study on the identified p38 MAPK signaling pathway inhibitor already revealed that the p38 MAPK downstream kinase MK2 is involved in proteasome activity regulation, which was unknown before this study. Moreover, the authors were able to show the chemotherapeutic potential of small molecule-triggered proteasome activation. Although further studies in more complex systems are undoubtedly still required, the present work thus opens new avenues for chemotherapeutic inventions, in particular for neurodegenerative disease treatments. It is therefore reasonable to assume that the present study has only been the first step in the field of proteasome activation and will foster future research into this direction." @default.
• W2702344249 created "2017-06-30" @default.
• W2702344249 creator A5022219229 @default.
• W2702344249 creator A5024191146 @default.
• W2702344249 creator A5078099512 @default.
• W2702344249 date "2017-06-01" @default.
• W2702344249 modified "2023-09-28" @default.
• W2702344249 title "Turning-ON Proteasomes" @default.
• W2702344249 cites W1603251764 @default.
• W2702344249 cites W1965575777 @default.
• W2702344249 cites W2012296420 @default.
• W2702344249 cites W2014996986 @default.
• W2702344249 cites W2172878595 @default.
• W2702344249 cites W2310322011 @default.
• W2702344249 cites W2553908226 @default.
• W2702344249 cites W2617007369 @default.
• W2702344249 doi "https://doi.org/10.1016/j.chembiol.2017.06.005" @default.
• W2702344249 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28644955" @default.
• W2702344249 hasPublicationYear "2017" @default.
• W2702344249 type Work @default.
• W2702344249 sameAs 2702344249 @default.
• W2702344249 citedByCount "4" @default.
• W2702344249 countsByYear W27023442492018 @default.
• W2702344249 countsByYear W27023442492019 @default.
• W2702344249 countsByYear W27023442492020 @default.
• W2702344249 countsByYear W27023442492021 @default.
• W2702344249 crossrefType "journal-article" @default.
• W2702344249 hasAuthorship W2702344249A5022219229 @default.
• W2702344249 hasAuthorship W2702344249A5024191146 @default.
• W2702344249 hasAuthorship W2702344249A5078099512 @default.
• W2702344249 hasBestOaLocation W27023442491 @default.
• W2702344249 hasConcept C27740335 @default.
• W2702344249 hasConcept C70721500 @default.
• W2702344249 hasConcept C86803240 @default.
• W2702344249 hasConcept C95444343 @default.
• W2702344249 hasConceptScore W2702344249C27740335 @default.
• W2702344249 hasConceptScore W2702344249C70721500 @default.
• W2702344249 hasConceptScore W2702344249C86803240 @default.
• W2702344249 hasConceptScore W2702344249C95444343 @default.
• W2702344249 hasIssue "6" @default.
• W2702344249 hasLocation W27023442491 @default.
• W2702344249 hasLocation W27023442492 @default.
• W2702344249 hasOpenAccess W2702344249 @default.
• W2702344249 hasPrimaryLocation W27023442491 @default.
• W2702344249 hasRelatedWork W2036587838 @default.
• W2702344249 hasRelatedWork W2051123135 @default.
• W2702344249 hasRelatedWork W2161744631 @default.
• W2702344249 hasRelatedWork W2291937760 @default.
• W2702344249 hasRelatedWork W2494898695 @default.
• W2702344249 hasRelatedWork W2913213802 @default.
• W2702344249 hasRelatedWork W3140240088 @default.
• W2702344249 hasRelatedWork W4284671611 @default.
• W2702344249 hasRelatedWork W4308751411 @default.
• W2702344249 hasRelatedWork W4321748974 @default.
• W2702344249 hasVolume "24" @default.
• W2702344249 isParatext "false" @default.
• W2702344249 isRetracted "false" @default.
• W2702344249 magId "2702344249" @default.
• W2702344249 workType "article" @default.